ESH 2017 | Finding novel treatment options for relapsed/progressing AML

Jorge Sierra

The long-term survival rate of acute myeloid leukemia (AML) patients who have relapsed, or whose disease is progressing, is poor. In this interview, Jorge Sierra, MD, PhD, of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the current treatment strategies and new agents being developed for for this patient group; including hypomethylating agents, monoclonal antibodies, CAR T-cells and FLT3 inhibitors. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).

Share this video